Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 3
2012 4
2013 3
2014 3
2015 3
2016 1
2018 2
2019 2
2020 1
2021 2
2022 2
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

23 results

Results by year

Filters applied: . Clear all
Page 1
Past, Present and Future of Oncolytic Reovirus.
Müller L, Berkeley R, Barr T, Ilett E, Errington-Mais F. Müller L, et al. Among authors: errington mais f. Cancers (Basel). 2020 Oct 31;12(11):3219. doi: 10.3390/cancers12113219. Cancers (Basel). 2020. PMID: 33142841 Free PMC article. Review.
Applications of coxsackievirus A21 in oncology.
Bradley S, Jakes AD, Harrington K, Pandha H, Melcher A, Errington-Mais F. Bradley S, et al. Among authors: errington mais f. Oncolytic Virother. 2014 Apr 10;3:47-55. doi: 10.2147/OV.S56322. eCollection 2014. Oncolytic Virother. 2014. PMID: 27512662 Free PMC article. Review.
Recent clinical experience with oncolytic viruses.
Donnelly OG, Errington-Mais F, Prestwich R, Harrington K, Pandha H, Vile R, Melcher AA. Donnelly OG, et al. Among authors: errington mais f. Curr Pharm Biotechnol. 2012 Jul;13(9):1834-41. doi: 10.2174/138920112800958904. Curr Pharm Biotechnol. 2012. PMID: 21740364 Review.
Combination of oncolytic Maraba virus with immune checkpoint blockade overcomes therapy resistance in an immunologically cold model of advanced melanoma with dysfunctional T-cell receptor signalling.
Armstrong E, Chiu MKL, Foo S, Appleton L, Nenclares P, Patrikeev A, Mohan N, Mclaughlin M, Bozhanova G, Hoebart J, Roulstone V, Patin E, Pedersen M, Kyula J, Ono M, Errington-Mais F, Bell J, Harrington KJ, Melcher A, Jennings V. Armstrong E, et al. Among authors: errington mais f. J Immunother Cancer. 2024 Jul 25;12(7):e009443. doi: 10.1136/jitc-2024-009443. J Immunother Cancer. 2024. PMID: 39060020 Free PMC article.
Efficacy of coxsackievirus A21 against drug-resistant neoplastic B cells.
Holmes M, Scott GB, Heaton S, Barr T, Askar B, Müller LME, Jennings VA, Ralph C, Burton C, Melcher A, Hillmen P, Parrish C, Errington-Mais F. Holmes M, et al. Among authors: errington mais f. Mol Ther Oncolytics. 2023 Mar 24;29:17-29. doi: 10.1016/j.omto.2023.03.002. eCollection 2023 Jun 15. Mol Ther Oncolytics. 2023. PMID: 37077714 Free PMC article.
Neoadjuvant Intravenous Oncolytic Vaccinia Virus Therapy Promotes Anticancer Immunity in Patients.
Samson A, West EJ, Carmichael J, Scott KJ, Turnbull S, Kuszlewicz B, Dave RV, Peckham-Cooper A, Tidswell E, Kingston J, Johnpulle M, da Silva B, Jennings VA, Bendjama K, Stojkowitz N, Lusky M, Prasad KR, Toogood GJ, Auer R, Bell J, Twelves CJ, Harrington KJ, Vile RG, Pandha H, Errington-Mais F, Ralph C, Newton DJ, Anthoney A, Melcher AA, Collinson F. Samson A, et al. Among authors: errington mais f. Cancer Immunol Res. 2022 Jun 3;10(6):745-756. doi: 10.1158/2326-6066.CIR-21-0171. Cancer Immunol Res. 2022. PMID: 35439304 Free PMC article.
Reovirus-induced cell-mediated immunity for the treatment of multiple myeloma within the resistant bone marrow niche.
Müller LME, Migneco G, Scott GB, Down J, King S, Askar B, Jennings V, Oyajobi B, Scott K, West E, Ralph C, Samson A, Ilett EJ, Muthana M, Coffey M, Melcher A, Parrish C, Cook G, Lawson M, Errington-Mais F. Müller LME, et al. Among authors: errington mais f. J Immunother Cancer. 2021 Mar;9(3):e001803. doi: 10.1136/jitc-2020-001803. J Immunother Cancer. 2021. PMID: 33741729 Free PMC article.
CD4 T cell dynamics shape the immune response to combination oncolytic herpes virus and BRAF inhibitor therapy for melanoma.
Bozhanova G, Hassan J, Appleton L, Jennings V, Foo S, McLaughlin M, Chan Wah Hak CM, Patin EC, Crespo-Rodriguez E, Baker G, Armstrong E, Chiu M, Pandha H, Samson A, Roulstone V, Kyula J, Vile R, Errington-Mais F, Pedersen M, Harrington K, Ono M, Melcher A. Bozhanova G, et al. Among authors: errington mais f. J Immunother Cancer. 2022 Mar;10(3):e004410. doi: 10.1136/jitc-2021-004410. J Immunother Cancer. 2022. PMID: 35338089 Free PMC article.
23 results